Skip to content

VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine

VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01385943
Acronym
EUNET
Enrollment
0
Registered
2011-06-30
Start date
2011-04-30
Completion date
2015-12-01
Last updated
2019-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer, Skin Lesions

Keywords

Reflectance Confocal Microscopy, Dermoscopy, Clinical Photos, Telemedicine

Brief summary

The goal of this study is to test a protocol that uses clinical pictures, confocal reflectance microscopy images and dermoscopic information in a telemedicine platform. This protocol will test the technologies and diagnostic performance of dermoscopy and confocal reflectance microscopy in a randomized prospective multicenter study in five different centers in Europe.

Detailed description

In vivo confocal reflectance microscopy (CRM) is a non-invasive method for the in vivo (without cutting into the skik) examination of skin tumors. CRM produces cellular images with resolution comparable to histopathology. The procedure is painless, takes about ten minutes and has no documented side effects. Studies performed in the past decade have correlated CRM features in benign (non-cancerous) and malignant (cancerous) skin lesions such as moles and melanomas, as well as features of inflammatory lesions (such as allergic skin reactions) to histopathology. Dermoscopy is a complementary technique that has been proven to be superior to the naked eye for the diagnosis of melanoma as well as some non-melanocytic skin tumors. Recently, correlation of dermoscopic and CRM structures has focused interest in the research in different groups that show that both are complementary and render in combination a better understanding of skin disease. In this study, patients from several research centers in Europe, with lesions suspicious for malignancy and scheduled for biopsy will be asked if they would like to participate in the study. If they consent to the study, first, a clinical photograph will be taken of the lesion. Second, a dermoscopic image will be taken of the lesion, and third, CRM images will be taken of the lesion. Finally, the biopsy will be performed as per the standard of care. The images will be sent over a secure, private internet connection to physicians specially trained in the interpretation of dermoscopic and CRM images. An electronic report will be completed and returned to the Study Coordinator, who will correlate the results with the histopathologic diagnosis.

Interventions

None listed

Sponsors

Hospital Clinic of Barcelona
CollaboratorOTHER
Hospital Universitario Ramon y Cajal
CollaboratorOTHER
Hospital del Mar
CollaboratorOTHER
University of Modena and Reggio Emilia
CollaboratorOTHER
Azienda USL Reggio Emilia - IRCCS
CollaboratorOTHER_GOV
Lucid, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Any skin tumor considered suspicious for malignancy under clinical non-aided examination * Histopathologic study of the tumor or short term follow up (3 months) to confirm benignity * Clinical information and images available * Adequate imaging by dermoscopy and CRM according to the protocol of the study * Consent form signed by the patient

Exclusion criteria

* Lesions with ulcerations obscuring more than 75% of the confocal mosaic field of view. * Lesions with clinically appreciable scar. * Lesions in locations not amenable to imaging with the confocal microscope.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy, in terms of sensitivity, specificity, positive and negative predictive values with respect to histopathologic diagnosis.Study participation will be no longer than three months for patients requiring follow up, and no longer than one office visit (approximately one hour) for patients being biopsied the same day they are imaged.Clinical pictures, dermoscopic pictures, confocal images and tissue biopsy will be obtained in a single study visit unless the physician determines that short-term (3 months) follow up is more appropriate, then the patient will be asked to return in three months for additional examination.

Secondary

MeasureTime frameDescription
Differences between dermoscopy/confocal microscopy, and dermoscopy plus confocal microscopyStudy participation will be no longer than three months for patients requiring follow up, and no longer than one office visit (approximately one hour) for patients being biopsied the same day they are imaged.Clinical pictures, dermoscopic pictures, confocal images and tissue biopsy will be obtained in a single study visit as described under Primary Outcomes, unless the physician determines that short-term (3 months) follow up is more appropriate, then the patient will be asked to return in three months for additional examination.

Countries

Italy, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026